What is CVE-2026-50034?

CVE-2026-50034 is a medium-severity vulnerability in Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt), classified under Cleartext Transmission of Sensitive Information. CVSS score: 6.5/10. Published 2026-06-19.

How severe is CVE-2026-50034?

Medium severity. CVSS v3 base score is 6.5 out of 10.

Vulnerability in Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt)

CVE-2026-50034

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

EPSS: 0.002 (11.3th percentile) — read the EPSS interpretation.

CVSS v3 metric

CVSS v3 base score 6.5 (Medium). Vector: CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N.

Affected products

Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt) — versions 0x0110_v1.1.0

Weakness classification (CWE)

CWE-319 — Cleartext Transmission of Sensitive Information

References

Frequently asked questions

What is CVE-2026-50034?: CVE-2026-50034 is a medium-severity vulnerability in Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt), classified under Cleartext Transmission of Sensitive Information. CVSS score: 6.5/10. Published 2026-06-19.
How severe is CVE-2026-50034?: Medium severity. CVSS v3 base score is 6.5 out of 10.